Biopure’s Case Study
1. How do you assess Biopure’s potential in the human market? The animal market? According to the demand for RBCs which can be used to treat chronic anemia and blood loss is increasing, Biopure Corporation products have the chance to grow in the future market. Like the rest of the world, the US is an ageing society. Population ageing is the big problem in the US. Between 2000 and 2050, the number of older people is projected to increase by 135%. (Figure1.) Moreover, the population aged 85 and over, which is the group most likely to need health and long-term care services, is projected to increase by 350%. [1] Over this time period, the proportion of the population that is over the age of 65 will increase from 12.7% in 2000 to 20.3% in 2050; the proportion of the population that is age 85 and older will increase from 1.6% in 2000 to 4.8% in 2050. Biopure products can be used to treat old age
people disease and provide the solution of Health and long-term care workforce issues. Besides, compare to competitors, Biopure product is less reply on human blood and it no need to be frozen. Those two advantages can provide the best solution of blood diseases like AIDS in developing countries. Biopure also has the potential in animal market. The small-animal veterinary practices expand faster. The AVMA’s most recent employment survey (December 2010) found that there were
61,502 vets in private practice. Of that number there were 41,381 vets in companion animal exclusive practices, and an additional 5,966 in companion animal predominant practices. [2] Biopure was the only company engaged in blood substitute for small animal market. Moreover, compare, Biopure has the FDA approval. Because of above reasons, Biopure also has the potential in animal market.
[1] Population ageing in the United States of America: implications for public programmes http://ije.oxfordjournals.org/content/31/4/776.full [2] Small Animal Veterinarian
people disease and provide the solution of Health and long-term care workforce issues. Besides, compare to competitors, Biopure product is less reply on human blood and it no need to be frozen. Those two advantages can provide the best solution of blood diseases like AIDS in developing countries. Biopure also has the potential in animal market. The small-animal veterinary practices expand faster. The AVMA’s most recent employment survey (December 2010) found that there were
61,502 vets in private practice. Of that number there were 41,381 vets in companion animal exclusive practices, and an additional 5,966 in companion animal predominant practices. [2] Biopure was the only company engaged in blood substitute for small animal market. Moreover, compare, Biopure has the FDA approval. Because of above reasons, Biopure also has the potential in animal market.
[1] Population ageing in the United States of America: implications for public programmes http://ije.oxfordjournals.org/content/31/4/776.full [2] Small Animal Veterinarian